Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03294486 : Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Age > 18 years.

2. Karnofsky performance status = 70.

3. Histologically confirmed primary glioblastoma with unequivocal progression after at
least the first line standard of care (concurrent chemoradiotherapy and adjuvant
chemotherapy) at least 3 months after the completion of radiotherapy.

4. At least one measurable lesion, according to RANO criteria.

5. Availability of biological material (tumor) for review processes.

6. No treatment with another investigational drug within 4 weeks before inclusion.

7. No surgery within 4 weeks before inclusion.

8. If reoperation is conducted an early post-surgery MRI, within 48 hours is needed.

9. Standard-of-Care MRI showing a target lesion performed within 2 weeks prior to

10. Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.

11. Non-enzyme inducing antiepileptic drugs (non-EIAED). Patients previously on EIAED must
be switched to non-EIAED at least 2 weeks prior to inclusion.

12. No previous cancer except: (i) cancer in remission for at least 5 years, (ii) skin
carcinoma, or (iii) in situ carcinoma of the uterine cervix.

13. Absence of any unstable disease (heart, liver, renal and respiratory failure).

14. Absence of serious conditions (as judged by the investigator) that could interfere
with the treatment (i.e. infection, immunosuppression defined as CD4+ lymphocytes <

15. Normal hematological functions: neutrophils = 1.5 x 109 cells/L, platelets = 100 x 109
cells/L and Hb = 10.0 g/dL).

16. Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN),
alkaline phosphatase and transaminases (ASAT, ALAT) < 3 x ULN.

17. Normal renal function: calculated (Cockcroft-Gault) or measured creatinine clearance =
60 mL/min.

18. Absence of pregnancy:

- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and 6 months beyond stop of
treatment and must have a negative serum or urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the
start of investigational product;

- Post menopause is defined as a documented serum follicle stimulating hormone
(FSH) level = 35 mIU/mL.

19. Females should not be breast feeding.

20. Patients must use a barrier method of contraception (e.g. condom for either male,
female patients or partners of female patients) during TG6002 treatment period and for
a minimum of 6 months following the last treatment with TG6002. In addition, to
minimize the risk of pregnancy, female patients or female partners of male patients
who are of childbearing potential must use an additional effective method of
contraception (e.g. one of the following: hormonal contraception, occlusive cap,
intrauterine device -IUD- or intrauterine system -IUS-, male sterilization, or true

21. Before patient inclusion and study related procedures (that would not have been
performed as part as standard care), written informed consent must be given according
to International Conference on Harmonization-Good Clinical Practices (ICH/GCP), and
national/local regulations.

22. Patient affiliated to social security. 23. Approval of participation, following
discussion with the multidisciplinary board of neuro-oncology, in the best interest of
patient and in absence of any other reasonable therapeutic alternative.

Exclusion Criteria:

1. Immunodeficiency:

- CD4+ lymphocyte count <200/µL, in any case ;

- HIV infection;

- Immunosuppressive therapy, including high dose corticosteroids (at a dose = 20 mg
per day of prednisone or equivalent, at the inclusion visit).

2. History of severe exfoliative skin condition (e.g. eczema or atopic dermatitis)
requiring systemic therapy for more than 4 weeks within 2 years of TG6002 treatment

3. History of a severe systemic reaction or side-effect as a result of a previous
smallpox vaccination, such as systemic vaccinia, eczema vaccinatum, encephalitis,
myocarditis, or pericarditis.

4. Patients with significant gastro-intestinal (GI) tract disease or resection leading to
significant impairment of GI absorption or bacterial overgrowth.

5. Known deficiency in dihydropyrimidine dehydrogenase (DPD).

6. Hypersensitivity to flucytosine.

7. Hypersensitivity to egg proteins.

8. Hypersensitivity to gentamicin.

9. History of severe drug allergy.

10. Received systemic anti-cancer therapy within 4 weeks prior to first administration of

11. Prior gene therapy.

12. Other medical condition or laboratory abnormality or active infection that in the
judgment of the principal investigator may increase the risk associated with study
participation or may interfere with interpretation of study results and /or otherwise
make the patient inappropriate for entry into this study.

13. Patient unable or unwilling to comply with the protocol requirements and/or unwilling
to sign an informed consent form.

14. Patient deprived of liberty or under legal protection measure.

15. Weight > 100kg.

16. Antiviral therapy (as ribavirin)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557